Pregnancy and Addiction 1
|
|
- Domenic Davidson
- 5 years ago
- Views:
Transcription
1 Disclaimers Addiction and Pregnancy 2017 Carl Christensen, MD, PhD, D-FASAM Clinical Assoc Prof, Psychiatry and OB/Gyn, Wayne State Univ School of Med, Detroit Mi Medical Director, Mich Health Professional Recovery Program June 15, 2017 No Financial Relationships Consultant, DEA/DOJ Consultant, BCBS Mich Methadone provider, Wayne State SOM Medical Director, Dawn Farm, Ann Arbor, MI Buprenorphine and naltrexone provider, A2 3 Qualifications: Carl Christensen Disclosures II Medications will be referred to in the generic whenever possible; will discuss FDA specific formulations We will be discussing off label use of buprenorphine and methadone; neither of these are approved by the FDA for use of opioid dependence in pregnancy WHY TALK ABOUT THIS? WHY TALK ABOUT THIS? Addiction and Pregnancy 11 Addiction and Pregnancy 12 Pregnancy and Addiction 1
2 WHY TALK ABOUT THIS? WHY TALK ABOUT THIS? NAS in Michigan You are here.. HEROIN Addiction and Pregnancy 13 Addiction and Pregnancy 16 NAS OPIOID USE rural Urban JAMA Pediatrics December 12, 2016 Online What is Addiction? 20 What is Addiction? Physiologic Dependence? Lack of willpower? An amoral condition? A brain disease? Pregnancy and Addiction 2
3 21 Physiologic Dependence: Tolerance and Withdrawal Tolerance: requiring increasing amounts of drug to get the same effect Withdrawal: the opposite effect of the drug when it is removed NEITHER of these imply chemical dependency (addiction) Lack of Willpower? 22 An amoral condition? Brain disease? 25 The Nucleus Accumbens: the Pleasure Center. Dopamine: the Pleasure DRUG 26 VTA: the gas tank : supplies dopamine to the Nucleus Accumbens Pregnancy and Addiction 3
4 Frontal Cortex: inhibits the What is the problem? Pleasure Center (maybe) Addiction is not a problem of drug WITHDRAWAL What is the problem? Drug WITHDRAWAL: the Hindbrain Addiction is not a problem of drug WITHDRAWAL.. It is a problem of: CRAVING LOSS OF CONTROL COMPULSIVE USE USE DESPITE CONSEQUENCES (the 4 Cs ) 31 Drug ADDICTION: the (primitive) Forebrain: 33 Pregnancy and Addiction 4
5 39 Why Can t Addicts Stop????? The relapse rate after undergoing detox approaches 100% The relapse rate when coming off meds (buprenorphine, methadone) is 90% But: their withdrawal is gone. SO: why do they relapse????? 40 Normal Volunteers Red: good blood flow Non users Cocaine users, 10 days sober Cocaine Users, 100 days sober High blood flow Low blood flow [C-11]d-threo-methylphenidate How Long to recover from Methamphetamine? Normal Control Methamphetamine Abuser (1 month abstinent) high low Treatment of Opioid Dependence (without) Pregnancy Methamphetamine Abuser (14 months abstinent) Volkow et al., J. Neuroscience, Medication Assisted Therapy (MAT): Agonists vs. Antagonists Drug Type Analogy Methadone Full Agonist High Octane Buprenorphine* Partial Low Octane Agonist Naltrexone Antagonist Water Medication Assisted Therapy (MAT): Methadone Pregnancy and Addiction 5
6 Medication Assisted Therapy (MAT buprenorphine Medication Assisted Therapy (MAT naltrexone BOTTOM LINE: (non-pregnant) In both controlled and retrospective studies, the success rate for most medications is between 40 and 60% (one to two years). When patients come off the medication, they relapse. Relapse may be associated with an increased chance of overdose and death. Benefits of Methadone Salsitz, ASAM, 2012 Reduction in death rates (Grondblah, 1990) Reduction in IVDU (Ball & Ross, 1991) Reduction in # of crime days (Ball & Ross) Reduced HIV seroconversion / HCV conversion IMPROVED OUTCOME AFTER INCARCERATION 59 Ball 1988: reduction in IVDU Ball 1988: reduction in IVDU ORT: yes or no??? 61 ORT: yes or no??? 62 Pregnancy and Addiction 6
7 Ball 1988: resumption of IVDU! Ball 1988: resumption of IVDU! ORT: yes or no??? 63 ORT: yes or no??? 64 Problems with methadone Buprenorphine Requires initial daily dosing first 90 days. Must be clean for 2 years before you can increase take homes! Methadone clinics may be a source of wet faces and wet places Stigma Judges will often try and force moms off methadonenow forbidden by the feds. A partial opiate agonist (less potent) Less analgesic effect Less respiratory depression <100 documented deaths in the U.S. (Soyka); PER YEAR WITH METHADONE Treats both pain and opiate dependency Different formulations are approved Addiction and Pregnancy 66 Buprenorphine +/-Naloxone: Buprenorphine: Available in 3 branded forms: Generic buprenorphine (Subutex ): sublingual OFF MARKET: Medicaid may not cover generic due to concerns about diversion. Bunavail : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Suboxone : sublingual buprenorphine + naloxone (Narcan ): prevents IV use* Zubsolv : ditto Formulations approved for PAIN: Buprenex : parenteral, used in the hospital setting. Butrans : weekly patch, 10 to 20 mcg/hr Belbuca : buccal film from mcg/24 hr. ANY of these will precipitate sudden withdrawal: only give when patient is going INTO withdrawal! Addiction and Pregnancy 67 * not FDA approved for pain Addiction and Pregnancy 68 Pregnancy and Addiction 7
8 What Formulation Should You Use? Buprenorphine long-term follow up: Fiellin, 2008 Generic buprenorphine avoids naloxone. It is more susceptible to diversion Use whatever their insurance will pay for!! 69 Concerns about buprenorphine It can be abused (mostly for withdrawal) It is unsafe when combined with sedatives & alcohol. It is an opioid. Relapse rates after detox exceed 90%. (Weiss, 2011) Vivitrol (injectable naltrexone) for opioid dependence This medication is not currently used during pregnancy; but may be used following delivery. 71 Addiction Tx in Russia Vivitrol: abstinence (50%) Kupitsky et al; Lancet 2011; 377: C / Pregnancy and Addiction 8
9 No Vivitrol, Control Treatment (40%) No Vivitrol; No Treatment (0%) Due to Vivitrol (naltrexone) Due to treatment Why the handcuffs? Vivitrol: craving CONTROL VIVITROL Vivitrol: craving Vivitrol: concerns CONTROL VIVITROL As with methadone and buprenorphine, when the medication is stopped, relapse may lead to death due to lack of tolerance. It would be very difficult to treat acute pain while on Vivitrol : suggestion is 20x normal dose. Ex: a patient underwent emergency operative laparoscopy 2 weeks after Vivitrol injection. He was treated with IV Dilaudid, 10 to 20 mg/hr. Pregnancy and Addiction 9
10 Luty 2003 Doc, when can I get off this sh*t medication? Can you detox off MAT? 101 women underwent detox during pregnancy 40 successfully detoxed. No adverse fetal effects documented BUT: Luty et al, J Sub Abuse Treat 24 (2003); ORT: yes or no??? 83 Maintenance vs. Detox? Kakko et al heroin addicts were started on buprenorphine/naloxone. 20 were detoxed off and offered counseling. 20 were kept on buprenorphine/naloxone and offered counseling. A year later. ORT: yes or no??? ORT: yes or no??? Can you taper off buprenorphine without relapse? 87 ORT: yes or no??? Pregnancy and Addiction 10
11 Buprenorphine in opioid dependence 654 patients enroll on buprenorphine for 2 weeks. 50% stay abstinent. They are tapered off and over 90% relapse. 360 remain, they go back on buprenorphine for 12 weeks, 50% stay abstinent. They taper off and 90+% relapse. Moral of the story: medications work as long as you take them. Your Baby Will Die If You Detox : Opioid Detox During Pregnancy Fetal death during pregnancy is rare. Patients can be successfully and safely detoxed. The lowest neonatal abstinence rates are seen with incarcerated patients (19%). Bell et al, AJOG 2016; 215: 374.e1-6 What is the Risk of Dying in and out of Treatment? Relative Risk= the risk of dying compared to someone who does NOT have opioid addiction RR= 1 without addiction. If RR >1 you are more likely to die. Mortality and M.A.T (bup and MTD) 122, 885 patients: OD mortality NO ADDICTION: RELATIVE RISK IS ONE (1) METHADONE BURPENORPHINE In treatment Out of treatment In Treatment Out of Treatment Sordo L et al. Mortality Risk during and after opioid substitution treatment: systematic review and meta0analysis of cohort studies. BMJ 2017; 357: J1550 Take Home Points: Mortality appears to decrease (29%) after starting medication assisted treatment. Mortality INCREASES after leaving treatment. Both the first two weeks IN treatment (methadone ) and OUT of treatment (methadone and buprenorphine) are the most dangerous periods. Treatment of Opioid Dependence During Pregnancy Pregnancy and Addiction 11
12 101 METHADONE the gold standard Was only approved for use for addiction in 1965; Dr. James Wardell started in Detroit in TIP 40: methadone is (was) the preferred treatment in pregnancy Buprenorphine was considered experimental. Improvement in neonatal outcomes documented by Ed Johnson and Andre Jones. Maternal Opioid Treatment: Human Experimental Research (MOTHER) MOTHER STUDY :NEJM 2010; 363: Addiction and Pregnancy 103 Double blinded, RCT Methadone vs. buprenorphine Contingency management (financial incentives $$$$) CBT (cognitive behavioral tx) Transportation, etc. NO polysubstance dependence x tobacco! Addiction and Pregnancy 104 MOTHER STUDY Sites Patients already on methadone are admitted to research unit for detox 6 mg MS/mg methadone (4 divided doses) Rescue doses prn Kept until stabilized THIS IS NOT FEASIBLE IN CLINICAL PRACTICE!!!!!!!!! Randomized to study meds on L & D Johns Hopkins, Baltimore MD T. Jefferson Univ., Philadelphia, PA Women & Infants, Providence RI Vanderbilt UMC, Nashville, TN St. Josephʼs Hlth Ctr. Toronto, Canada Wayne State Univ., Detroit, Michigan University of VT, Burlington, VT Addiction Clinic Vienna, Austria Addiction and Pregnancy 105 Addiction and Pregnancy 106 Pregnancy and Addiction 12
13 Methadone vs. Buprenorphine: the MOTHER study Measure Methadone Buprenorphine Amount of MS required # of days in hospital Duration of treatment for NAS Birthweight % preterm delivery 19 7* Positive drug screen at delivery 15% 9%* Dropped out 18% 33 MOTHER study. Buprenorphine exposed neonates exhibited fewer stress-abstinence signs, were less excitable less hypertonia better selfregulation and required less handling than methadone-exposed neonates. Jones Finnegan & Kaltenbach Drugs 2012 Addiction and Pregnancy Who should NOT go on buprenorphine? Patients who are: Already on methadone (>35 mg) Active hepatitis C (high LFTs) Unable to engage in treatment Taking benzos Plan on mixing bup with their opiates Are diverting Can t get insurance coverage Buprenorphine-->Methadone? NOT necessary! Can continue buprenorphine Risk of NAS is decreased (severity and duration)with buprenorphine as compared to methadone! Again, neither of these is APPROVED for treatment of opioid dependence during pregnancy. Addiction and Pregnancy 116 Addiction and Pregnancy 118 Methadone à Buprenorphine? Methadone: Has a LONG half life MOTHER study dropouts were partially due to attempts to convert high dose methadone to buprenorphine Current expert opinion is to limit to patients on mg. Safest course may be to remain on methadone. Addiction and Pregnancy 119 Current Management: Eleonore Hutzel Recovery Center/ Tolan Clinic, Detroit Mich Patients who present on SHORT acting opioids: buprenorphine Patients who present on long acting opioids or methadone: methadone Benzodiazepine use must stop immediately or they will be referred for methadone. 120 Pregnancy and Addiction 13
14 Management of Labor/Postpartum in the Recovering Patient Labor may be a trigger for relapse Epidurals should be encouraged Donʼt discharge patients with short acting opiates whenever possible! For C/S patients: need to involve family, social work, addictionist when dispensing opiates RESIDENTS: Confirm EVERYTHING the patient tells you!! 136 Who is Behind the Opioid Epidemic? Addiction and Pregnancy 135 Unintentional overdose deaths involving opioid analgesics parallel per capita sales of opioid analgesics in morphine equivalents by year, U.S., Rates of Opioid Sales, OD Deaths, and Treatment, Opioid Sales KG/10,000 Opioid Deaths/100,000 * Number of Opioid sales 600 Deaths (mg/person) '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 Source: National Vital Statistics System, multiple cause of death dataset, and DEA ARCOS Rate sales deaths treatment 1999 CDC. MMWR Year * 2007 opioid sales figure is preliminary. 139 Michigan is 10 th in the US: 140 WHY do doctors over prescribe? 107 prescriptions/100 people. The Four D s: Dated Dishonest Duped Disabled Pregnancy and Addiction 14
15 141 The Four D s: 142 The Four D s: Dishonest? Dated Disabled Duped Dishonest? Dated Disabled Duped 143 The Four D s: 144 The Four D s: Dishonest? Dated Disabled Duped Dishonest? Dated Disabled Duped Pressure on Doctors? 146 The Four D s: Dishonest Dated Disabled Duped The 5 th D: defamation Baker D. History of The Joint Commission s Pain Standards: Lessons for Today s Prescription Opioid Epidemic. JAMA, published online February 23, by 2004 this phrase was deleted from the accreditation standards manual. Lembke, Anna. Why Doctors Prescribe Opioids to known Opioid Abusers. n engl j med 367;17 nejm.org october 25, 2012 Pregnancy and Addiction 15
16 152 Naltrexone vs. Naloxone The Opioid Epidemic & Naloxone (Narcan ) Rescue Developed for Families Against Narcotics Naltrexone Oral (Rivea ) or IM (Vivitrol ) Slow onset Long acting (hours to weeks) Tightest binding to brain Used for PREVENTION of overdose (FDA) Naloxone IV, IM, SC or IN (Narcan, Evzio ) Rapid Onset Short acting (minutes) Less tightly bound Used for TREATMENT of overdose (FDA) Naloxone formulations: (0.4 mg) 154 Intranasal (I.N.): ADAPT (4mg/2mg!) Who is at Greatest Risk? 156 Fentanyl on Urine Drug Screen Pregnant Patient Abstinence > 2 weeks: treatment; jail; relapse. Discontinuing MAT: methadone; buprenorphine; Vivitrol (naltrexone). Mixing opioids with sedatives: alcohol, benzodiazepines, muscle relaxers FENTANYL 50% of UDS samples with heroin are pos for Fentanyl Pregnancy and Addiction 16
17 157 How To Do A Naloxone Rescue Naloxone in Pregnancy Make Sure They are Not Breathing (always) Call 911 Do Rescue Breaths (not compressions) Give Naloxone Resume Rescue Breaths Repeat Naloxone every 3 mins To review videos: go to ccmdphd on YouTube due to the risk of induced withdrawal, use of naloxone should be avoided during pregnancy and used only when absolutely necessary ASAM textbook of addiction medicine Naloxone in Pregnancy That statement is no longer operative. Ron Ziegler, President Nixon s Press Secretary Contact Information: Carl Christensen Office Cell: Website: Pregnancy and Addiction 17
Pregnancy, MAT and Addiction
Pregnancy, MAT and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine William Morrone, DO, MPH, DABAM Covenant Hospital
More informationPregnancy and Addiction
Pregnancy and Addiction Carl Christensen, MD, PhD, D-FASAM Clinical Associate Professor, OB Gyn & Psychiatry Wayne State University School of Medicine November 16, 2016 1 Educational Objectives At the
More informationWho is Behind the Opioid Epidemic?
Safe and Effective Management of Pain and Addiction CARL CHRISTENSEN, MD PHD MEDICAL DIRECTOR, DAWN FARM CLINICAL ASSOCIATE PROFESSOR, WSU SCHOOL OF MEDICINE WWW.CHRISTENSENRECOVERY.COM Tonight s Talk:
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More informationDisclosures. Topics of today s training 4/24/2017. Evolving Treads in Medication Assisted Treatment. Christopher J Davis D.O.
Evolving Treads in Medication Assisted Treatment Christopher J Davis D.O. CAADC, FASAM Medical Director, The Ranch of Pennsylvania Medical Director, Pyramid Healthcare Diplomate of The American Board of
More informationDoes Treatment Work? Disclaimers. What is Addiction? Lack of Willpower? Addiction and Recovery News. Physiologic Dependence: Tolerance and Withdrawal
Disclaimers Does Treatment Work? Carl Christensen MD PhD, FASAM Clinical Associate Professor, WSU School of Medicine Medical Director, Dawn Farm Medical Director, Mich Health Recovery Prof Program n n
More informationDoes Treatment Work? Disclaimers. What is Recovery? Does Treatment Work? 5/16/17. To Get This PowerPoint and copies of the Articles.
Does Treatment Work? Carl Christensen MD PhD, FASAM Medical Director, Dawn Farm Clinical Associate Professor, WSU School of Medicine Medical Director, Mich Health Recovery Prof Program Advisory Board,
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationMedication-Assisted Treatment. What Is It and Why Do We Use It?
Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite
More informationMedication Assisted Treatment
Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationIdentification and Treatment of Opioid Use Disorders in Primary Care Settings
Identification and Treatment of Opioid Use Disorders in Primary Care Settings 17th Annual Primary Care Symposium February 24, 2018 Kelly S. Barth, DO Associate Professor, Psychiatry & Internal Medicine
More informationMedication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationInjectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP
Injectable naltrexone (XR-NTX) A RETROSPECTIVE STUDY OF ITS ACCEPTANCE IN A COMMUNITY RECOVERY SETTING BRIANNE FITZGERALD MSN, PMHNP, CARN-AP Overview Gavin Foundation Injectable naltrexone Community report
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationArwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry
The State of Medicine in Addiction Recovery Arwen Podesta, MD ABIHM, ABAM, Forensic Psychiatry www.podestawellness.com 504-252-0026 http://www.addictionpolicy.org/ Overview Addiction is a serious, chronic
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationAgenda. 1 Opioid Addiction in the United States. Evidence-based treatments for OUD. OUD Treatment: Best Practices. 4 Groups: Our Model
Agenda 1 Opioid Addiction in the United States 2 Evidence-based treatments for OUD OUD Treatment: Best Practices 4 Groups: Our Model 2 Groups is a national network of clinics providing affordable, evidencebased
More informationAnyone Can Become Addicted. Anyone.
Anyone Can Become Addicted. Anyone. PAStop.org Family Toolkit Seeking Drug Abuse Treatment: Know What to Ask Trying to identify the right treatment programs for a loved one can be a difficult process.
More informationChanging Course: statewide efforts to combat the opioid epidemic in California
Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries
More informationOPIOID SUBSTITUTION THERAPY RISKS & BENEFITS
OPIOID SUBSTITUTION THERAPY RISKS & BENEFITS LEO O. LANOIE, MD, MPH, FCFP, CCSAM, ABAM, FISAM, MRO Dr. Leo Lanoie, 2017 DISCLAIMER In the past year I have accepted funds from Purdue for speaking OPIOID
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationTrends and Challenges: The Kentucky Opioid Crisis. Jason Smith, MD PhD University of Louisville
Trends and Challenges: The Kentucky Opioid Crisis Jason Smith, MD PhD University of Louisville Brief Introduction I am by no means an expert I have no financial disclosures Jokes are meant to be lighthearted
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More information2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders
The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationTHE OPIOID CRISIS 9/19/2018 DEFINING THE CRISIS DEFINING THE CRISIS NUMBER OF OPIOID-RELATED OVERDOSE DEATHS IN ALABAMA
THE OPIOID CRISIS DEFINING THE CRISIS KATHLEEN DUPPER, MD MEDICAL DIRECTOR, HUNTSVILLE RECOVERY 19 th Annual Perinatal Conference: The Opioid Crisis September 21, 2018 DEFINING THE CRISIS NUMBER OF OPIOID-RELATED
More informationThe role of behavioral interventions in buprenorphine treatment of opioid use disorders
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
More informationTopics of today s training
Extended Release Naltrexone Vivitrol Christopher J Davis D.O. CAADC, FASAM Medical Director, Brightwater Landing Medical Director, Pyramid Healthcare Diplomate of The American Board of Addition Medicine
More informationUSE OF BUPRENORPHINE FOR CHRONIC PAIN
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND
More informationMedication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc.
Medication Assisted Treatment: Right for you, Right for your Recovery? Robert Matylewicz, DO, FASAM Medical Director, Clarity Way Inc. Elements Behavioral Health Diplomate, American Board of Addiction
More informationInitiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis
Initiation of MAT for Opioid Use Disorder in the Hospitalized Patient and ER Setting: Promoting Best Outcomes in the Wake of an Opioid Crisis Sponsored by the Florida Alcohol and Drug Abuse Association
More informationMAT in the Corrections Setting
MEDICATION ASSISTED TREATMENT AND CORRECTIONS Frank Filippelli, DO, PhD September 2017 MAT in the Corrections Setting Who Does This Affect? What is MAT and What is the Evidence of Efficacy? Emphasis on
More informationNoel Schenk MD. Davis Behavioral Health
Noel Schenk MD Davis Behavioral Health Michael Botticelli Director of National Drug Control Policy What is Addiction? Addiction is defined as a chronic, relapsing brain disease that is characterized by
More informationHARM REDUCTION & TREATMENT. Devin Reaves MSW
HARM REDUCTION & TREATMENT Devin Reaves MSW The mission of PAHRC is to promote the health, dignity, and human rights of individuals who use drugs and communities impacted by drug use. Recognizing that
More informationMAT 101: TREATMENT OF OPIOID USE DISORDER
MAT 101: TREATMENT OF OPIOID USE DISORDER WITH SPECIAL EMPHASIS ON BUPRENORPHINE/NALOXONE ICADD May 22, 2018 Alicia Carrasco, MD Debby Woodall, LCSW, ACADC Magni Hamso, MD, MPH Terry Reilly Health Services
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationMaternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC
Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC Objectives 1. Discuss the effects of opiate addiction on mothers and infants. 2. Discuss a Medical Home
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More information9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)
9/9/2016 Prior Authorization Form PASSPORT HEALTH PLAN KENTUCKY MEDICAID Buprenorphine Products This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for Responsible
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationDiscover the Hope: Opiate Treatment and Recovery
Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationWhat is the strategy?
What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health
More informationOpioid Dependence During Pregnancy: Balancing Risk/Benefit
Opioid Dependence During Pregnancy: Balancing Risk/Benefit Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology Vanderbilt University Acknowledgement: R01DA015713 Conflicts: None Outline I. Epidemiology
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationKRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH
KRISANNA DEPPEN, MD FAMILY MEDICINE, ADDICTION MEDICINE GRANT MEDICAL CENTER-OHIOHEALTH COLUMBUS, OH IF THESE MOMS REALLY CARED ABOUT THEIR BABIES, THEY WOULD JUST QUIT Those who can quit, often do Addiction
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationAnesthetics, Local a / or Anesthesia, Epidural a / or Anesthesia, Obstetrical a / or Pain, Postoperative a / or Postpartum Period a
Appendix 1. Literature Search Databases Years Search Terms Pubmed 01/1966 1. Analgesics, Opioid a / or Opioid-related Disorders a / PsycINFO EMBASE Cochrane 09/2016 or Heroin a / or Heroin Dependence a
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationMethadone and Pregnancy
Methadone and Pregnancy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Charissa Patricelli, MD, CCFP, ABAM Clinical Associate Professor, Dept. of Family Practice UBC American Board of Addiction Medicine
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationLatest Research on Addiction and Treatment
Latest Research on Addiction and Treatment Joshua D Lee MD MSc joshua.lee@nyumc.org / @DrJoshuaDLee Associate Professor NYU School of Medicine, Department of Population Health Disclosures, LeeJD Grants:
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationWhat Is Heroin? Examples of Opioids. What Science Says about Opioid Use Disorder and Its Treatment 6/27/2016
What Science Says about Opioid Use Disorder and Its Treatment Perilou Goddard, Ph.D. Department of Psychological Science Northern Kentucky University Examples of Opioids Agonists (activate opioid receptors)
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationResponding to the Opioid Addiction Epidemic
Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist,
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationJohann Hari. Truths 2/29/2016. From the street to the NICU. Treatment works
From the street to the NICU Richard Christensen, PA, CAS Johann Hari Treatment works Truths Disconnect with pregnant women seeking treatment Disconnect between community and science Medication is not a
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationMedication-assisted opioid addiction treatments: OB/GYN
5/13/16se Medication-assisted opioid addiction treatments: OB/GYN In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex, and a buprenorphine/naloxone
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationTreating Opioid Addiction
Treating Opioid Addiction Some people who start taking opioid pain medications eventually have serious problems with them and become addicted. Every day, 68 people die in the US from opioid overdose. More
More informationEarl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction
Earl Hightower's Remarks 2014 National Rx Drug Abuse Summit Medication Assisted Treatment for Opiate Addiction Thank you, Chairman Rogers, for holding this important Summit and helping to bring attention
More informationMaternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015
Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples
More informationOverdose Treatment. Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine.
Part B 2 3 4 Overdose Treatment Naloxone is the drug of choice to treat methadone and other opioid overdose including heroin and morphine. Specifically used to counteract lifethreatening depression of
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationPennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story
Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story Sarah Sharfstein Kawasaki, MD Director of Addictions Services, Pennsylvania Psychiatric
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationDisclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond
Women and opioid use disorder: Optimizing care during pregnancy and beyond Susanne Astrab Fogger, DNP, PMHNP-BC, CARN-AP, FAANP Ashley L. Hodges, PhD, CRNP, WHNP-BC Disclosures Dr. Fogger has nothing to
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D.. Executive Director, Physicians for Responsible Opioid Prescribing Senior Scientist, Heller School
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More informationMedication Assisted Treatment of an Opioid Use Disorder. J. Craig Allen, MD. Medical Director, Rushford
Medication Assisted Treatment of an Opioid Use Disorder J. Craig Allen, MD. Medical Director, Rushford Learning objectives At the conclusion of this activity, participants will be able to: Understand
More informationResponding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction
Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, MD Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis
More informationNaloxone Statewide Standing Order. Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties
Naloxone Statewide Standing Order Cheryl A. Viracola, PharmD Pharmacy Programs Manager, Community Care of Wake and Johnston Counties Objectives Review the US & NC trends on opioid overdose Understand key
More informationOpioid Use Disorder- Pregnancy Principles and Myths. Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center
Opioid Use Disorder- Pregnancy Principles and Myths Brian Iriye MD and Farzad Kamyar MD High Risk Pregnancy Center History of NAS/NOWS Prior to 1875 infants not thought to be affected Congenital Morphinism
More informationOpioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
More informationMedication-Assisted Treatment (MAT) for Opioid Use Disorders
Medication-Assisted Treatment (MAT) for Opioid Use Disorders Sybil Marsh MA MD FASAM Department of Family Medicine and Community Health Case Western Reserve University/UHCMC Learning Objective 1 Following
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationMAT for Opioid Dependence. MAT and Pain Management. Epidemiology. Epidemiology. Factors Impacting Pain Perception 9/23/2014
MAT for Opioid Dependence Methadone maintenance treatment (MMT) Buprenorphine/naloxone (suboxone) Buprenorhine/naloxone (BupNX) Buprenorphine SL Parenteral naltrexone (P-ntx) Oral naltrexone (ntx) MAT
More informationMedication Assisted Treatment as an alternative in Drug Courts*
Medication Assisted Treatment as an alternative in Drug Courts* National Drug Court Institute *portions of this presentation include adapted slides by Frances Levin, MD, Joshua Lee, MD, & Laurence Westreich,
More information